Abstract: The present invention provides a nanoparticle comprising a poly(alkyl cyanoacrylate) homopolymer, or copolymer, at least one active agent and an anionic and radical inhibitor, wherein the anionic and radical inhibitor is a compound having the following formula: wherein R1 is H; and R3, R4, R5, R6 and R7 are independently selected from the group consisting of —H, —OH, C1-C6 alkoxide, C1-C6 alkyl, halides, carboxylic acid, ketone or aldehyde; wherein the anionic and radical inhibitor is present in an amount of 0.001 to 15 wt %, as well as a process suitable for manufacture of the nanoparticle.

Abstract: The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Abstract: Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.

Abstract: Disclosed are pharmaceutical compositions including a plurality of nanoparticles including a compound of the following structure (1) or a pharmaceutically acceptable salt thereof. Also disclosed are methods of their use and preparation.

Abstract: The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Abstract: Described herein is a hydrophobic anti-cancer drug encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.

Abstract: The invention relates to a nanoparticle comprising copolymeric or homopolymeric compounds which comprise cyanoacrylate subunits according to formula 2A, wherein each R1 is independently selected from the group consisting of 2-ethylhexyl, 2-phenylethyl, neopentyl, 1-pentyl, 2-pentyl, 3-pentyl, 3,3-dimethyl-1-butyl, 3-methylbutyl, -heptyl, 2-heptyl, and 3-heptyl; and wherein the nanoparticle further comprises an active agent. The invention also provides compositions comprising the nanoparticles, and the nanoparticles for use in therapy or diagnosis, such as in the treatment of cancer or an infection, or for use in diagnostic imaging.

Abstract: The present invention provides a nanoparticle comprising a poly(alkyl cyano-acrylate) homopolymer, or copolymer, at least one active agent and an anionic and radical inhibitor, wherein the anionic and radical inhibitor is a compound having the following formula: wherein R1 is H; and R3, R4, R5, R6 and R7 are independently selected from the group consisting of —H, —OH, C1-C6 alkoxide, C1-C6 alkyl, halides, carboxylic acid, ketone or aldehyde; wherein the anionic and radical inhibitor is present in an amount of 0.001 to 15 wt %, as well as a process suitable for manufacture of the nanoparticle.

Abstract: The invention is related to the field nanoparticles and medical use. In particular, it relates to cabazitaxel (CBZ) as active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer.

Abstract: A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.

Abstract: The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Abstract: Described herein is a hydrophobic anti-cancer drug encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.

Abstract: The present invention is generally directed to improvements in the treatment of cancer and diseases in the central nervous system. A new drug delivery system is provided, method for producing it and medical uses.

Abstract: Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.

Abstract: A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.